Dr. Katherine Matthay is the Mildred V. Strouss Professor of translational oncology at the University of California San Francisco, and is internationally known for her work in advancing therapy of neuroblastoma. She is the leader of the Pediatric Malignancies program in the Helen Diller Family Comprehensive Cancer Center at UCSF. She served as North American continental president for the International Society of Pediatric Oncology, and is currently the president of the Advances in Neuroblastoma Research Association. She initiated several landmark randomized trials in neuroblastoma in the Children’s Oncology Group, improving outcome with high dose therapy and bone marrow transplant followed by isotretinoin, and then with anti-GD2 monoclonal antibody therapies. She established the NCI-funded New Approaches to Neuroblastoma Therapy (NANT) clinical trials consortium for targeted therapy of neuroblastoma, now in its 17th year. She has been a leader in the development of targeted radiotherapy for neuroblastoma with the 131I-mIBG, which she initiated at UCSF in 1987. She cares for children with relapsed and resistant neuroblastoma from many corners of the world, providing new therapies to try to overcome tumor resistance.